Summary
The term ‘benefit-risk ratio’ is often used as a general term linked to the use of a medicine. To balance risk and benefit is, however, a very complex exercise. For most medicines the benefits are limited to a few indications and for an individual patient there is usually only a single benefit sought but the potential risks are multiple.
Perceptions of risks versus benefits are influenced to a great extent by the context in which they occur. Thus, perception of risk may be different to actual risk. In the end in any given situation, the acceptable risk-to-benefit balance is an individual judgement on the part of the patient or the prescriber.
For newer medicines, where there is likely to be limited experience, conser-vative estimates of the overall merit seem preferable so that the prescriber will use the drug critically. Subsequently, re-evaluation of the risk-to-benefit balance is necessary as greater knowledge of efficacy and adverse effects is acquired.
It is possible to provide a general ‘principle of threes’ structure for a merit assessment based upon the concepts of seriousness, duration and incidence as related to disease indication, disease amelioration by a medicine, and the adverse effects ascribed to the medicine. This allows a rapid first comparison of medicines for a given indication.
In using this general conceptual model in a transparent fashion for a given hypothesis and context, it is possible to identify the essential data used and assumptions involved that make up a merit statement. The quality and value, particularly of risk data, is problematic. Risk perception is an issue that needs to be clearly identified alongside a merit analysis. A simple merit assessment should pave the way for more focused studies.
Similar content being viewed by others
References
Bullinger M. Indices versus profiles: advantages and disadvantages. In: Walker SR, Rosser RM, editors. Quality of life assessment. Dordrecht: Kluwer, 1993: 209–20
FASS Läkemedel i Sverige. Stockholm, Sweden: LINFO Läkemedels-information AB, 1995
CIOMS Working Group III. Guidelines for preparing core clinical safety information on drugs. Geneva: WHO, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edwards, I.R., Wiholm, BE. & Martinez, C. Concepts in Risk-Benefit Assessment. Drug-Safety 15, 1–7 (1996). https://doi.org/10.2165/00002018-199615010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199615010-00001